Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

This is a placebo-controlled Phase 2 ulcerative colitis study in a moderate-to-severe population, so a positive readout is far from routine. The primary endpoint, Week 12 clinical response on the modified Mayo Clinic Score, is a standard and achievable endpoint and is less demanding than remission, which supports some chance of success. It also includes an endoscopic component, so the outcome is not purely symptom driven. Still, UC studies often face meaningful placebo response, patient heterogeneity, and background-treatment noise, all of which can compress treatment-placebo separation. The brief summary suggests multiple GS-1427 treatment groups against placebo, which helps dose finding but can split sample size across arms and increase statistical volatility. Gilead lowers execution and data-quality risk, and the trial reaching primary completion without an obvious operational problem is mildly reassuring. But the input provides no prior efficacy signal, biomarker support, or other de-risking evidence. Overall, solid design and sponsor quality are outweighed by normal Phase 2 efficacy risk and limited prior-data support.

GS-1427 targets α4β7 integrin, the same validated mechanism as vedolizumab (Entyvio), which demonstrated clear efficacy in UC Phase 2/3 trials. The oral formulation offers a potential convenience advantage. Phase 1 data showed favorable receptor occupancy, selectivity, and tolerability. However, several factors create uncertainty: (1) the historical Phase 2 UC PTSR is only 45%; (2) prior oral α4β7 programs (PTG-100) showed only modest efficacy; (3) enrollment was significantly reduced from 423 to 228 participants mid-trial, which could reflect adaptive design optimization or early safety/futility signals; (4) results have not been disclosed despite primary completion ~29 days ago. The validated mechanism supports a probability somewhat above generic base rate, but the oral delivery challenge, enrollment reduction, and lack of any disclosed efficacy data in patients keep uncertainty high. The clinical response endpoint at Week 12 using mMCS is standard and well-precedented. Balancing positive mechanistic validation against oral delivery risk and the enrollment cut, I estimate approximately 50% probability of positive results.

This is a Phase 2 Gilead trial for GS-1427 in ulcerative colitis with a well-validated primary endpoint (modified Mayo Clinic Score clinical response at Week 12). The endpoint definition is clinically meaningful and the trial design appears sound. However, Phase 2 trials historically have ~70% failure rates, and the UC therapeutic landscape is highly competitive with established TNF inhibitors, JAK inhibitors, and integrin antagonists. No prior efficacy data for GS-1427 is visible in the trial fields, and the results have not yet been disclosed despite the primary completion date passing 29 days ago. Gilead's resources and experience are a positive factor, but without visible prior signal, the intrinsic probability of a positive outcome is modestly below even odds, around 40%. The binary call is NO since yesProbability < 0.5.

This is a Phase 2 trial for ulcerative colitis, a competitive space where many mechanisms fail. The primary endpoint is a standard composite clinical response at Week 12, which is a reasonable but not definitive bar. The trial is past its primary completion date, suggesting data readout is imminent, which reduces operational risk. However, there is no prior clinical data provided for GS-1427, introducing significant uncertainty about its novel mechanism. Gilead is a capable sponsor, but the lack of any efficacy signal disclosure to date is a material risk. The binary success hurdle in a placebo-controlled study is high. The intrinsic odds appear slightly below even.

This Phase 2 trial evaluates GS-1427 vs placebo in moderate-severe UC patients using clinical response at Week 12 per modified Mayo Score (mMCS): ≥2-point decrease, ≥30% reduction, rectal bleeding improvement. Endpoint is high-quality, standardized, with placebo rates typically 20-30% and drug arms 40-60% for successes; sensitive to efficacy. Population standard for UC trials, no enrichment. Gilead's strong execution minimizes operational risks, reliable data collection/endoscopy. No prior data on GS-1427 (novel asset?) raises uncertainty; lacks Phase 1b signals or MOA precedent like IL-23/JAK inhibitors with ~50% Phase 2 hit rates. UC competitive; failures common from immunogenicity/variability. Solid double-blind design, but fixed n/powers standard, no futility. Primary completion 29 days past (est. Mar 2026), status active not recruiting; low disclosure risk as Gilead discloses promptly post-topline. Historical Phase 2 UC success ~40%; derate for unknown prior to 44%.

This Phase 2 trial for GS-1427 in ulcerative colitis has passed its primary completion date by 29 days, yet no results are posted. Gilead's historical disclosure practices suggest that negative or neutral trials are often delayed, while positive results are announced more rapidly. The primary endpoint, clinical response at Week 12 using the modified Mayo Clinic Score, is a standard efficacy measure. However, the mechanism of action for GS-1427 is not detailed in the provided fields, introducing uncertainty regarding its biological plausibility in a crowded IBD landscape. Given the high failure rate for novel UC therapies and the silence post-completion, the probability of a clearly positive outcome is below 50%. The sponsor has no urgent catalyst pressure to withhold good news, making the delay a negative signal. I estimate a 35% chance of positive results.

Phase 2 UC trials face high placebo response rates (30-40%), making clinical response endpoints challenging. GS-1427 is a novel TNF receptor inhibitor with promising preclinical data, but no prior human efficacy signals exist. The modified Mayo score is validated but subjective; endoscopy subscore requires central reading quality. Gilead's operational execution in IBD is mixed—previous filgotinib UC program showed efficacy but safety concerns derailed it. Primary completion was March 4, 2026 (29 days past), suggesting data lock is imminent or complete. 'Active Not Recruiting' status with past completion date indicates analysis ongoing. Disclosure risk is elevated given Gilead's material event disclosure practices. UC Phase 2 success rates historically hover around 45-55% for novel mechanisms. Slight edge to YES given Gilead's portfolio prioritization and typical signal-seeking Phase 2 designs, but uncertainty remains substantial due to lack of human data and endpoint softness.

The Phase 2 SWIFT trial (NCT06290934) evaluates GS-1427 (emvistegrast), an oral selective α4β7 integrin inhibitor, for moderate to severe ulcerative colitis (UC). The primary endpoint is clinical response at Week 12. The α4β7 pathway is clinically validated by vedolizumab (Entyvio), a highly successful biologic for UC. Furthermore, mechanistic proof-of-concept for an oral small molecule has been recently established by Morphic's MORF-057, which achieved a 45.7% clinical response at Week 12 in its Phase 2a trial, prompting a $3.2B acquisition by Eli Lilly. Gilead's Phase 1 data in healthy volunteers (published early 2026) demonstrated favorable pharmacokinetics, with steady-state exposure reached by day 5 and an excellent safety profile consisting entirely of grade 1 adverse events. Given the heavily de-risked biological target, the positive precedent of a competitor's oral compound, and GS-1427's clean Phase 1 profile, the probability of achieving a statistically significant clinical response over placebo is substantially higher than the industry baseline for Phase 2 UC trials.

The trial is a Phase 2 study of GS-1427 in participants with moderately to severely active ulcerative colitis. The primary endpoint is clinical response at Week 12, which is a decrease from baseline in the modified Mayo Clinic Score (mMCS) of ≥ 2 points and at least a 30% reduction from baseline. Given the specific and measurable primary endpoint, the study's active status, and the sponsor's reputation, there's a reasonable expectation of positive results. However, the uncertainty remains as it's a Phase 2 trial and the outcome depends on various factors including patient population and operational execution.